- 201. LYMPHOSARCOMA AXILLA
- [ ] (UMLS (ICD9CM) C0153707) =Neoplastic Process
| - 223. Lysis of adhesions of spermatic cord
- [ ] (UMLS (ICD9CM) C0195022) =Therapeutic or Preventive Procedure
|
- 202. LYMPHOSARCOMA HEAD
- [ ] (UMLS (ICD9CM) C0153704) =Neoplastic Process
| - 224. Lysis of adhesions of spinal cord and nerve roots
- [ ] (UMLS (ICD9CM) C0196521) =Therapeutic or Preventive Procedure
|
- 203. LYMPHOSARCOMA INGUIN
- [ ] (UMLS (ICD9CM) C0153708) =Neoplastic Process
| - 225. Lysis of adhesions of tongue
- [ ] (UMLS (ICD9CM) C0192181) =Therapeutic or Preventive Procedure
|
- 204. Lymphosarcoma involving intrapelvic lymph nodes
- [ ] (UMLS (ICD9CM) C0153709) =Neoplastic Process
| - 226. Lysis of adhesions of trachea or larynx
- [ ] (UMLS (ICD9CM) C0176493) =Therapeutic or Preventive Procedure
|
- 205. Lymphosarcoma involving intrathoracic lymph nodes
- [ ] (UMLS (ICD9CM) C0153705) =Neoplastic Process
| - 227. Lysis of peritoneal adhesions
- [ ] (UMLS (ICD9CM) C0198664) =Therapeutic or Preventive Procedure
|
- 206. Lymphosarcoma involving lymph nodes of multiple sites
- [ ] (UMLS (ICD9CM) C0153711) =Neoplastic Process
| - 228. Lysis of pharyngeal adhesions
- [ ] (UMLS (ICD9CM) C0192249) =Therapeutic or Preventive Procedure
|
- 207. Lymphosarcoma involving spleen
- [ ] (UMLS (ICD9CM) C0153710) =Neoplastic Process
| - 229. Lysis of posterior synechiae
- [ ] (UMLS (ICD9CM) C0197652) =Therapeutic or Preventive Procedure
|
- 208. Lymphosarcoma, unspecified site, extranodal and solid organ sites
- (UMLS (ICD9CM) C0375076) =Neoplastic Process
| - 230. Lysis of vulvar adhesions
- [ ] (UMLS (ICD9CM) C0195098) =Therapeutic or Preventive Procedure
|
- 209. LYN
- [This gene plays a role in signal transduction. ( NCI )] (UMLS (NCI) C0812307) LYN Gene;
v-YES-1 Yamaguchi Sarcoma Viral Related Oncogene Homolog Gene =Gene or Genome | - 231. Lysodren
- (UMLS (NCI) C0702007) =Organic Chemical; Pharmacologic Substance ;
|
- 210. Lynoral
- (UMLS (NCI) C0699367) =Steroid; Pharmacologic Substance; Hormone
| - 232. lysogeny
- [phenomenon by which a temperate phage integrates itself into the DNA of a bacterial host, establishing a type of symbiotic relation between prophage and bacterium which results in the perpetuation of the prophage in all the descendants of the bacterium; upon induction by various agents, such as chemicals or ultraviolet radiation, the phage is released, which then becomes virulent and lyses the bacterium. ( CSP )] (UMLS (CSP) C0024352) =Biologic Function =genetic transduction;
|
- 211. LYPRESSIN
- [The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing an LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. ( MSH )] (UMLS (NCI) C0024328) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Hormone =[HS702] POSTERIOR PITUITARY;
TO BE DELETED INGREDIENT PREPARATIONS;
ADH;
| - 233. lysokinase
- [ ] (UMLS (CSP) C0599410) =Amino Acid, Peptide, or Protein; Enzyme
|
- 212. lysergic acid
- [ ] (UMLS (CSP) C0369632) =Organic Chemical ;
| - 234. lysolecithin
- [derivatives of phosphatidylcholines obtained by their partial hydrolysis which removes one of the fatty acid moieties. ( CSP )] (UMLS (CSP) C0024360) =Lipid =lysophospholipid;
|
- 213. lysine
- [essential aminoacid necessary for optimal growth in infants and for maintenance of nitrogen equilibrium in adult humans. ( CSP )] (UMLS (CSP) C0024337) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Amino Acids, Diamino;
Amino Acids, Essential;
primary aminoacid;
[TN503] AMINO ACIDS/PROTEINS, ORAL =LYSINE ACETATE;
LYSINE HYDROCHLORIDE;
polylysine;
LYSINE ACETATE;
LYSINE HYDROCHLORIDE;
LYSINE 334 MG;
LYSINE 500 MG;
LYSINE 100 MG/15ML;
LYSINE 10.5 MG/ML;
LYSINE 11.8 MG/ML;
LYSINE 1575 MG/100ML;
LYSINE 2.65 MG/ML;
LYSINE 252 MG/100ML;
LYSINE 255 MG/100ML;
LYSINE 3.68 MG/ML;
LYSINE 310 MG;
LYSINE 318 MG;
LYSINE 360 MG/100ML;
LYSINE 38.25 MG;
LYSINE 4.46 MG/ML;
LYSINE 475 MG/100ML;
LYSINE 5.1 MG/ML;
LYSINE 5.25 MG/ML;
LYSINE 510 MG;
LYSINE 535 MG/100ML;
LYSINE 580 MG;
LYSINE 6.24 MG/ML;
LYSINE 6.77 MG/ML;
LYSINE 620 MG/100ML;
LYSINE 624 MG;
LYSINE 7.35 MG/ML;
LYSINE 730 MG/100ML;
LYSINE 8.93 MG/ML;
LYSINE 9 MG/ML;
LYSINE 93 MG/GM | - 235. lysophospholipid
- [phospholipid that lacks one of its fatty acyl chains; an intermediate formed during digestion of dietary and biliary phospholipids. ( CSP )] (UMLS (CSP) C0024367) =Lipid =phosphatide;
=lysolecithin |
- 214. lysine analog
- [ ] (UMLS (CSP) C0597826) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance
| - 236. lysosome
- [morphologically heterogeneous cytoplasmic particles characterized by their content of hydrolytic enzymes and the structure-linked latency of these enzymes, normally involved in the process of localized intracellular digestion; the activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured. ( CSP )] (UMLS (NCI) C0024369) =Cell Component =organelle;
|
- 215. Lysine Biosynthesis
- [The chemical reactions and pathways resulting in the formation of lysine, 2,6-diaminohexanoic acid. [GOC:go_curators] ( GO )] (UMLS (NCI) C1156601) Lysine Biosynthesis Pathway;
=Molecular Function | - 237. lysozyme
- [A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17. ( MSH )] (UMLS (CSP) C0026794) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Enzyme =O glycosidase;
|
- 216. lysinemia
- [ ] (UMLS (CSP) C0596875) =Disease or Syndrome ;
| - 238. Lyssavirus
- [A genus of the family RHABDOVIRIDAE that includes RABIES VIRUS and other rabies-like viruses. ( MSH )] (UMLS (CSP) C0206546) =Virus
|
- 217. Lysis
- [Tissue structure disintegration and destruction due to action of endogenous or/and exogenous lytic substances which include but not limited to naturally occuring or laboratory designed proteolytic enzymes, glycosidases, detergents, pore-forming proteins, immune complexes, etc. Tissue lysis plays role in pathogenesis of a number of conditions e.g. protozoal infections, ischemic tissue injury, and autoimmune disorders. It is also used as a basis for non-surgical treatment modality to remove or minimize presence of abnormal tissue, e.g. adhesions. ( NCI )] (UMLS (NCI) C0024348) =Pathologic Function
| - 239. Lysuron
- (UMLS (NCI) C1449502) =Organic Chemical; Pharmacologic Substance
|
- 218. LYSIS CORTICAL ADHESION
- [ ] (UMLS (ICD9CM) C0176036) =Therapeutic or Preventive Procedure
| - 240. Lytechinus
- [A genus of SEA URCHINS in the family Toxopneustidae possessing trigeminate ambulacral plating. ( MSH )] (UMLS (CSP) C0599394) =Invertebrate ;
|
- 219. Lysis of adhesions and decompression of cranial and peripheral nerves
- [ ] (UMLS (ICD9CM) C0176066) =Therapeutic or Preventive Procedure
| - 241. lytic
- [Having to do with lysis. In biology, lysis refers to the disintegration of a cell by disruption of its plasma membrane. Lysis can be caused by chemical or physical means (e.g., high-energy sound waves) or by a virus infection. ( NCI )] (UMLS (NCI) C0439680) =Qualitative Concept
|
- 220. Lysis of adhesions of hand
- [ ] (UMLS (ICD9CM) C0187661) =Therapeutic or Preventive Procedure
| - 242. Lytic Bone Lesion
- (UMLS (NCI) C0741592) =Laboratory or Test Result
|
- 221. Lysis of adhesions of nose
- [ ] (UMLS (ICD9CM) C0189071) =Therapeutic or Preventive Procedure
| - 243. Lytic Metastatic Bone Lesion
- (UMLS (NCI) C0302313) =Finding
|
- 222. Lysis of adhesions of ovary and fallopian tube
- (UMLS (ICD9CM) C0195580) =Therapeutic or Preventive Procedure
| - 244. Lytton Rancheria of California
- (UMLS (HL7) C1554364) =Population Group =NativeEntityContiguous;
|
home
